New data from the ongoing Phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab demonstrated an ORR of 82 percent, a CR rate of 63 percent and MRD negativity rate of 67 percent in patients with R/R follicular lymphoma.
Genmab and AbbVie announced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 82 percent, a complete response (CR) rate…